Lumark

RSS

lutetium (177 Lu) chloride

Authorised
This medicine is authorised for use in the European Union.

Overview

Lumark contains the radioactive compound lutetium (177Lu) chloride and is used for radiolabelling other medicines. Radiolabelling is a technique for tagging (or labelling) medicines with radioactive compounds so they can carry radioactivity to where it is needed in the body, for example, the site of a tumour.

Lumark is to be used to radiolabel medicines that have been specifically developed for use with lutetium (177Lu) chloride.

This EPAR was last updated on 29/09/2020

Authorisation details

Product details
Name
Lumark
Agency product number
EMEA/H/C/002749
Active substance
lutetium (177Lu) chloride
International non-proprietary name (INN) or common name
lutetium (177 Lu) chloride
Therapeutic area (MeSH)
Radionuclide Imaging
Anatomical therapeutic chemical (ATC) code
V10
Publication details
Marketing-authorisation holder
I.D.B. Radiopharmacy B.V.
Revision
9
Date of issue of marketing authorisation valid throughout the European Union
18/06/2015
Contact address
I.D.B. Holland B.V.
Weverstraat 17
5111 PV Baarle-Nassau
The Netherlands

Product information

17/09/2020 Lumark - EMEA/H/C/002749 - PSUSA/00010391/201912

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Therapeutic radiopharmaceuticals

Therapeutic indication

Lumark is a radiopharmaceutical precursor. It is not intended for direct use in patients. This medicinal must be used only for the radiolabelling of carrier molecules, which have been specifically developed and authorised for radiolabelling with this radionuclide.

Assessment history

Changes since initial authorisation of medicine

How useful was this page?

Add your rating
Average
1 rating
1 rating